Information Provided By:
Fly News Breaks for October 31, 2019
MDCO
Oct 31, 2019 | 10:06 EDT
Jefferies analyst Biren Amin said new disclosures in The Medicines Company's 10-Q regarding 2022 convertible notes introduces an additional risk as the company's balance sheet is not strong and if holders convert by December the company could require additional near-term funding. The 10-Q stated that if the notes are called and the company can't raise sufficient funds that "there is substantial doubt about the company's ability to continue as a going concern," Amin pointed out. He keeps a Hold rating on Medicines Co. shares.
News For MDCO From the Last 2 Days
There are no results for your query MDCO